BNGO

Bionano Genomics, Inc. Common Stock

1.15

USD

BNGO Earnings Reports

Positive Surprise Ratio

BNGO beat 10 of 29 last estimates.

34%

Next Report

Date of Next Report

Mar 30, 2026

Estimate for Q4 25 (Revenue/ EPS)

$8.01M

-$1.42

Implied change from Q3 25 (Revenue/ EPS)

+8.73%

-10.69%

Implied change from Q4 24 (Revenue/ EPS)

-1.87%

-91.03%

Bionano Genomics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, BNGO reported earnings of -1.59 USD per share (EPS) for Q3 25, beating the estimate of -1.94 USD, resulting in a 18.39% surprise. Revenue reached 7.37 million, compared to an expected 7.01 million, with a 5.12% difference. The market reacted with a +3.40% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 5 analysts forecast an EPS of -1.42 USD, with revenue projected to reach 8.01 million USD, implying an decrease of -10.69% EPS, and increase of 8.73% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Belite Bio, Inc - ADR

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.55

Actual

-$0.38

Surprise

+31.80%

Apogee Therapeutics, Inc. Common Stock

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$1.07

Actual

-$1.03

Surprise

+4.31%

Wave Life Sciences Ltd. Ordinary Shares

Report Date

Feb 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-10.54%

ANI Pharmaceuticals, Inc.

Report Date

Feb 27, 2026 For Q4 25

Estimate

$2.03

Actual

$2.33

Surprise

+14.48%

Mannkind Corporation

Report Date

Feb 26, 2026 For Q4 25

Estimate

$0.01

Actual

-$0.05

Surprise

-440.14%

Zymeworks Inc.

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.42

Actual

-$0.55

Surprise

-29.53%

uniQure N.V.

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.96

Actual

-$0.56

Surprise

+41.97%

Fortrea Holdings Inc. Common Stock

Report Date

Feb 26, 2026 For Q4 25

Estimate

$0.16

Actual

$0.09

Surprise

-44.92%

UroGen Pharma Ltd. Ordinary Shares

Report Date

Mar 02, 2026 For Q4 25

Estimate

-$0.51

Actual

-$0.54

Surprise

-5.37%

Compugen Ltd

Report Date

Mar 02, 2026 For Q4 25

Estimate

$0.05

Actual

$0.60

Surprise

+1076.47%

FAQ

What were Bionano Genomics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Bionano Genomics, Inc. Common Stock reported EPS of -$1.59, beating estimates by 18.39%, and revenue of $7.37M, 5.12% above expectations.

How did the market react to Bionano Genomics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 3.4%, changed from $1.47 before the earnings release to $1.52 the day after.

When is Bionano Genomics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 30, 2026.

What are the forecasts for Bionano Genomics, Inc. Common Stock's next earnings report?

Based on 5 analysts, Bionano Genomics, Inc. Common Stock is expected to report EPS of -$1.42 and revenue of $8.01M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.